Showing 671-680 of 4110 results for "".
Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvPractically Here
https://practicaldermatology.com/series/the-practical-dermatology-podcast/practically-here/18186/Discover the Practical Dermatology podcast, taking you into the world of dermatology care with in-depth conversations with physicians, medical aesthetics industry, and other healthcare experts.The Importance of Keeping Up with New Developments
https://practicaldermatology.com/conferences/maui-derm-2024/the-importance-of-keeping-up-with-new-developments/20257/Practical Dermatology® Chief Medical Editor Neal Bhatia, MD, chats with Resident Of Distinction Award-winner Dawn Queen, MD, at Maui Derm 2024, about the critical role of continuing to educate yourself as a practitioner, and the importance of keeping on top of new drugs and therapies in daily practiHow Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.How Can Telemedicine Best Access the Inaccessible?
https://practicaldermatology.com/topics/practice-management/how-can-telemedicine-best-access-the-inaccessible/23954/Adam Friedman, MD, describes a new teledermatology program that brings care where it’s needed most.Unsolicited Offers: How Should Dermatology Practice Owners Respond?
https://practicaldermatology.com/topics/practice-management/unsolicited-offers-how-should-dermatology-practice-owners-respond/23836/Unsolicited offers have become more common. Here’s what you need to know.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.Teledermatology Update
https://practicaldermatology.com/topics/practice-management/teledermatology-update/20146/Many dermatologists and dermatologic surgeons adopted teledermatology or began to use it more frequently throughout the COVID pandemic. Many consultations and post-operative follow-up appointments were handled through telemedicine platforms. Anthony Rossi, MD talks about the benefits of this technolDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)